Trade Mind Medicine (MindMed) Inc. Subordinate Voting Shares - MNMD CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Mind Medicine (MindMed) Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 3.9 |
| Open* | 3.84 |
| 1-Year Change* | -44.91% |
| Day's Range* | 3.66 - 3.84 |
| 52 wk Range | 2.88-25.65 |
| Average Volume (10 days) | 13.99K |
| Average Volume (3 months) | 419.73K |
| Market Cap | 182.17M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 38.60M |
| Revenue | N/A |
| EPS | -2.57 |
| Dividend (Yield %) | N/A |
| Beta | 2.13 |
| Next Earnings Date | Aug 9, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 21, 2023 | 3.69 | -0.16 | -4.16% | 3.85 | 3.86 | 3.66 |
| Sep 20, 2023 | 3.90 | -0.06 | -1.52% | 3.96 | 4.05 | 3.77 |
| Sep 19, 2023 | 4.01 | 0.02 | 0.50% | 3.99 | 4.05 | 3.93 |
| Sep 18, 2023 | 4.05 | -0.09 | -2.17% | 4.14 | 4.15 | 4.01 |
| Sep 15, 2023 | 4.15 | -0.05 | -1.19% | 4.20 | 4.30 | 4.06 |
| Sep 14, 2023 | 4.29 | 0.25 | 6.19% | 4.04 | 4.32 | 4.03 |
| Sep 13, 2023 | 4.04 | -0.06 | -1.46% | 4.10 | 4.28 | 4.00 |
| Sep 12, 2023 | 4.19 | -0.09 | -2.10% | 4.28 | 4.49 | 4.17 |
| Sep 11, 2023 | 4.28 | 0.37 | 9.46% | 3.91 | 4.29 | 3.91 |
| Sep 8, 2023 | 3.99 | 0.05 | 1.27% | 3.94 | 3.99 | 3.85 |
| Sep 7, 2023 | 3.91 | -0.03 | -0.76% | 3.94 | 4.02 | 3.90 |
| Sep 6, 2023 | 4.09 | 0.23 | 5.96% | 3.86 | 4.10 | 3.85 |
| Sep 5, 2023 | 3.95 | 0.02 | 0.51% | 3.93 | 4.04 | 3.89 |
| Sep 1, 2023 | 4.08 | -0.09 | -2.16% | 4.17 | 4.29 | 4.07 |
| Aug 31, 2023 | 4.13 | 0.28 | 7.27% | 3.85 | 4.29 | 3.85 |
| Aug 30, 2023 | 3.84 | 0.04 | 1.05% | 3.80 | 3.95 | 3.80 |
| Aug 29, 2023 | 3.85 | 0.13 | 3.49% | 3.72 | 3.87 | 3.72 |
| Aug 28, 2023 | 3.79 | 0.00 | 0.00% | 3.79 | 3.95 | 3.78 |
| Aug 25, 2023 | 3.79 | -0.02 | -0.52% | 3.81 | 3.88 | 3.70 |
| Aug 24, 2023 | 3.83 | -0.20 | -4.96% | 4.03 | 4.06 | 3.81 |
Mind Medicine (MindMed) Inc. Subordinate Voting Shares Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2019 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 66.331 | 93.854 | 33.03 | 1.10477 | 5.42921 |
| Selling/General/Admin. Expenses, Total | 30.162 | 59.065 | 14.399 | 0.456936 | 3.10517 |
| Research & Development | 32.969 | 34.789 | 18.631 | 2.04904 | |
| Depreciation / Amortization | 3.2 | 0.006618 | 0.275 | ||
| Interest Expense (Income) - Net Operating | |||||
| Operating Income | -66.331 | -93.854 | -33.03 | -1.10477 | -5.42921 |
| Interest Income (Expense), Net Non-Operating | 1.69 | -0.445 | -0.907 | 0 | 0.02751 |
| Other, Net | 7.845 | 0.106 | 0 | -0.0725 | |
| Net Income Before Taxes | -56.796 | -94.193 | -33.937 | -1.10477 | -5.47421 |
| Net Income After Taxes | -56.796 | -93.036 | -33.937 | -1.10477 | -5.47421 |
| Net Income Before Extra. Items | -56.796 | -93.036 | -33.937 | -1.10477 | -5.47421 |
| Net Income | -56.796 | -93.036 | -33.937 | -1.10477 | -5.47421 |
| Income Available to Common Excl. Extra. Items | -56.796 | -93.036 | -33.937 | -1.10477 | -5.47421 |
| Income Available to Common Incl. Extra. Items | -56.796 | -93.036 | -33.937 | -1.10477 | -5.47421 |
| Diluted Net Income | -56.796 | -93.036 | -33.937 | -1.10477 | -5.47421 |
| Diluted Weighted Average Shares | 30.8575 | 27.3785 | 17.7489 | 0.37943 | 6.92954 |
| Diluted EPS Excluding Extraordinary Items | -1.84059 | -3.39815 | -1.91206 | -2.91167 | -0.78998 |
| Diluted Normalized EPS | -1.84059 | -3.39815 | -1.91206 | -1.22171 | -0.78998 |
| Unusual Expense (Income) | 0.641219 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 20.862 | 13.9 | 16.983 | 16.943 | 18.505 |
| Selling/General/Admin. Expenses, Total | 8.263 | 5.07 | 9.211 | 7.617 | 8.264 |
| Research & Development | 11.799 | 8.03 | 6.972 | 8.526 | 9.441 |
| Operating Income | -20.862 | -13.9 | -16.983 | -16.943 | -18.505 |
| Interest Income (Expense), Net Non-Operating | 1.232 | 1.153 | 0.498 | -0.007 | 0.018 |
| Other, Net | -5.185 | 7.844 | 0 | -0.007 | 0.036 |
| Net Income Before Taxes | -24.815 | -4.903 | -16.485 | -16.957 | -18.451 |
| Net Income After Taxes | -24.815 | -4.903 | -16.485 | -16.957 | -18.451 |
| Net Income Before Extra. Items | -24.815 | -4.903 | -16.485 | -16.957 | -18.451 |
| Net Income | -24.815 | -4.903 | -16.485 | -16.957 | -18.451 |
| Income Available to Common Excl. Extra. Items | -24.815 | -4.903 | -16.485 | -16.957 | -18.451 |
| Income Available to Common Incl. Extra. Items | -24.815 | -4.903 | -16.485 | -16.957 | -18.451 |
| Diluted Net Income | -24.815 | -4.903 | -16.485 | -16.957 | -18.451 |
| Diluted Weighted Average Shares | 38.0773 | 37.7314 | 29.2963 | 28.2434 | 28.1489 |
| Diluted EPS Excluding Extraordinary Items | -0.6517 | -0.12994 | -0.5627 | -0.60039 | -0.65548 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.6517 | -0.12994 | -0.5627 | -0.60039 | -0.65548 |
| Depreciation / Amortization | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 |
| Unusual Expense (Income) |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2019 | |
|---|---|---|---|---|---|
| Total Current Assets | 146.055 | 137.215 | 81.519 | 2.91521 | 6.73654 |
| Cash and Short Term Investments | 142.142 | 133.539 | 80.094 | 0.017801 | 3.01645 |
| Cash & Equivalents | 0.017801 | ||||
| Short Term Investments | |||||
| Total Receivables, Net | 0.005042 | ||||
| Prepaid Expenses | 3.913 | 3.676 | 1.425 | 0.021357 | 0.0342 |
| Total Assets | 169.993 | 164.002 | 81.519 | 2.91521 | 11.9615 |
| Property/Plant/Equipment, Total - Net | 0 | ||||
| Other Long Term Assets, Total | 0.331 | 0 | |||
| Total Current Liabilities | 17.892 | 10.408 | 3.008 | 0.143617 | 1.9612 |
| Accounts Payable | 2.111 | 4.178 | 2.022 | 0.143617 | 1.9612 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 19.076 | 12.338 | 5.651 | 0.19749 | 1.9612 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 150.917 | 151.664 | 75.868 | 2.71772 | 10.0003 |
| Common Stock | 0 | 0 | 5.51407 | 15.3218 | |
| Additional Paid-In Capital | 344.758 | 288.29 | 120.22 | 0.792485 | |
| Retained Earnings (Accumulated Deficit) | -194.468 | -137.672 | -44.636 | -3.62328 | -5.32143 |
| Other Equity, Total | 0.627 | 1.046 | 0.284 | 0.034436 | |
| Total Liabilities & Shareholders’ Equity | 169.993 | 164.002 | 81.519 | 2.91521 | 11.9615 |
| Total Common Shares Outstanding | 37.9791 | 28.1022 | 20.96 | 0.40552 | 11.0999 |
| Other Liabilities, Total | 1.184 | 1.93 | 2.643 | 0.053873 | 0 |
| Other Current Assets, Total | 2.87101 | 3.6859 | |||
| Cash | 142.142 | 133.539 | 80.094 | 3.01645 | |
| Intangibles, Net | 3.689 | 6.869 | 0 | 5.225 | |
| Goodwill, Net | 19.918 | 19.918 | 0 | ||
| Accrued Expenses | 5.877 | 6.23 | 0.986 | ||
| Other Current Liabilities, Total | 9.904 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 132.413 | 146.055 | 156.51 | 109.09 | 123.227 |
| Cash and Short Term Investments | 129.409 | 142.142 | 154.519 | 105.741 | 120.472 |
| Cash | 129.409 | 142.142 | 154.519 | 105.741 | 120.472 |
| Prepaid Expenses | 3.004 | 3.913 | 1.826 | 3.172 | 2.755 |
| Other Current Assets, Total | 0.165 | 0.177 | |||
| Total Assets | 155.529 | 169.993 | 180.907 | 134.277 | 149.234 |
| Property/Plant/Equipment, Total - Net | |||||
| Goodwill, Net | 19.918 | 19.918 | 19.918 | 19.918 | 19.918 |
| Intangibles, Net | 2.898 | 3.689 | 4.479 | 5.269 | 6.089 |
| Total Current Liabilities | 24.096 | 17.892 | 26.038 | 7.871 | 10.559 |
| Accounts Payable | 2.32 | 2.111 | 0.824 | 0.732 | 3.332 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 25.185 | 19.076 | 27.314 | 9.773 | 12.429 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | |||||
| Total Equity | 130.344 | 150.917 | 153.593 | 124.504 | 136.805 |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Additional Paid-In Capital | 348.986 | 344.758 | 342.415 | 296.734 | 291.931 |
| Retained Earnings (Accumulated Deficit) | -219.283 | -194.468 | -189.565 | -173.08 | -156.123 |
| Other Equity, Total | 0.641 | 0.627 | 0.743 | 0.85 | 0.997 |
| Total Liabilities & Shareholders’ Equity | 155.529 | 169.993 | 180.907 | 134.277 | 149.234 |
| Total Common Shares Outstanding | 38.2901 | 37.9791 | 37.5411 | 28.4474 | 28.1615 |
| Accrued Expenses | 6.687 | 5.877 | 7.467 | 7.139 | 7.227 |
| Other Liabilities, Total | 1.089 | 1.184 | 1.276 | 1.902 | 1.87 |
| Other Current Liabilities, Total | 15.089 | 9.904 | 17.747 | ||
| Other Long Term Assets, Total | 0.3 | 0.331 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2019 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -56.796 | -93.036 | -33.937 | -1.10477 | -5.47421 |
| Cash From Operating Activities | -50.139 | -45.824 | -23.597 | -0.206066 | -3.19971 |
| Cash From Operating Activities | 0.006618 | ||||
| Non-Cash Items | 7.079 | 42.716 | 8.279 | 0.686323 | 0.0725 |
| Changes in Working Capital | -3.602 | 3.037 | 2.061 | 0.205774 | 1.927 |
| Cash From Investing Activities | 0 | -0.297 | 0 | -0.211048 | |
| Capital Expenditures | -0.310361 | ||||
| Other Investing Cash Flow Items, Total | 0 | -0.297 | 0 | 0.099313 | |
| Cash From Financing Activities | 59.051 | 98.824 | 96.704 | 0.285516 | 9.90205 |
| Issuance (Retirement) of Stock, Net | 59.458 | 98.824 | 97.099 | 0.285516 | 9.90205 |
| Issuance (Retirement) of Debt, Net | 0 | ||||
| Foreign Exchange Effects | -0.309 | 0.742 | 0.284 | -0.001382 | |
| Net Change in Cash | 8.603 | 53.445 | 73.391 | -0.132972 | 6.70234 |
| Amortization | 3.18 | 2.616 | 0 | 0.275 | |
| Deferred Taxes | 0 | -1.157 | 0 | ||
| Financing Cash Flow Items | -0.407 | 0 | -0.395 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -24.815 | -56.796 | -51.893 | -35.408 | -18.451 |
| Cash From Operating Activities | -13.331 | -50.139 | -37.29 | -27.993 | -12.866 |
| Amortization | 0.791 | 3.18 | 2.39 | 1.6 | 0.78 |
| Non-Cash Items | 8.967 | 7.079 | 13.861 | 8.062 | 3.792 |
| Changes in Working Capital | 1.726 | -3.602 | -1.648 | -2.247 | 1.013 |
| Cash From Investing Activities | 0 | 0 | 0 | 0 | |
| Other Investing Cash Flow Items, Total | 0 | 0 | 0 | 0 | |
| Cash From Financing Activities | 0.583 | 59.051 | 58.635 | 0.424 | -0.166 |
| Financing Cash Flow Items | 0 | -0.407 | -0.407 | -0.407 | -0.407 |
| Issuance (Retirement) of Stock, Net | 0.583 | 59.458 | 59.042 | 0.831 | 0.241 |
| Foreign Exchange Effects | 0.015 | -0.309 | -0.365 | -0.229 | -0.035 |
| Net Change in Cash | -12.733 | 8.603 | 20.98 | -27.798 | -13.067 |
| Capital Expenditures | |||||
| Deferred Taxes | 0 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Mind Medicine (MindMed) Company profile
Mind Medicine (MindMed) Inc is a biopharmaceutical company that develops clinical-stage psychedelic medicines to treat brain health disorders. The New York-based firm specialises in psychiatry, addiction, pain management and neurology.
Founded in May 2019, MindMed has several drug candidates targeting serotonin, dopamine and acetylcholine systems. These products are based on psychedelic and empathogen substances. The company’s main drug candidate is MM-120, which is a proprietary, pharmaceutically optimised form of LSD. The medication is being developed to treat generalised anxiety disorder (GAD). MindMed is also researching the drug in various dosing regimens for the treatment of attention deficit hyperactivity disorder, also known as attention-deficit/hyperactivity disorder (ADHD), as well as chronic pain.
MM-110, the company’s second advanced drug, is being developed to treat opioid withdrawal. The MM-110, also known by the non-proprietary name zolunicant, is a form of 18-methoxycoronaridine, an ibogaine congener.
The company’s third medicine candidate is MM-402, or R(-)-MDMA, a proprietary form of the R-enantiomer of MDMA (3,4-methylenedioxymethamphetamine). The medicine is being developed for the treatment of core symptoms of autism spectrum disorder.
In addition to its advanced stage drugs, the company also has several earlier stage research programmes through external collaboration, including a multi-year exclusive partnership with University Hospital Basel (UHB) in Switzerland.
MindMed does not own or operate any manufacturing facilities. All clinical and non-clinical materials are supplied by third-party contract manufacturing organisations, or CMOs.
MindMed went public on 27 February 2020 on the Toronto-based NEO Exchange under the ticker ‘MMED’. It is listed on Nasdaq under the symbol ‘MNMD’ and in Germany under the ticker ‘BGHM’.
| Industry: | Biotechnology & Medical Research (NEC) |
1166 Alberni Steet
Suite 1604
VANCOUVER
BRITISH COLUMBIA V6E 3Z3
CA
Income Statement
- Annual
- Quarterly
News
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com